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anti-cytokine immunization ͉ anti-VEGF antibody therapy ͉ tumor neoangiogenesis ͉ cancer treatment O rgans developing during embryogenesis, and tissues regenerating after wound healing or ischemia, need a new blood supply to provide oxygen and nutrients. This state requires the in situ formation of new vessels, which depends on endothelial cell proliferation and migration. In this process, termed ''neoangiogenesis,'' vascular endothelial growth factor A (VEGF-A) is a key regulator of the migration and growth of the endothelial cells (1) .
Neoangiogenesis is also required for the growth of malignant tumors cells (2) and depends on the production of VEGF by the cancer cells or by stromal cells. In the tumor, the induction of VEGF is chiefly controlled by hypoxia (3) . Besides its prominent pathogenic role in neoangiogenic and metastatic processes (4), extracellular VEGF, together with other cytokines, also contributes to deleterious effects in the microenvironment of the tumor, including the inhibition of dendritic cell maturation, which contribute to immune escape of cancer cells (5) .
Various approaches have been developed in treating cancer patients to counteract the pathogenic effects of VEGF. These treatments include toxic drugs such as tyrosine kinase receptor inhibitors (6) , soluble receptors (7), and mAbs against VEGF (8) or its receptors (9) , all of which have been used in clinical trials. In particular, Ferrara et al. (10) have reported that anti-VEGF mAb (bevacizumab) in combination with chemotherapy increased the overall survival of patients with different types of tumors, including colorectal and breast cancer. However, bevacizumab may generate adverse side effects, including thrombosis (11), bleeding, hypertension, and proteinuria (12) . Moreover, mAbs therapy is expensive and cumbersome. These limitations have prompted scientists to investigate alternative strategies, including active immunization, to block VEGF overproduction (12, 13) .
We report here that immunization of mice with a murine (m)VEGF derivative immunogen termed ''mVEGF kinoid,'' consisting of a keyhole limpet hemocyanin (KLH)-mVEGF heterocomplex, induces neutralizing autoantibodies to mVEGF and that such an immunization of BALB/c mice challenged with syngeneic CT26 colorectal tumor cells resulted in the inhibition of lung metastases. We also show that human (h)VEGF kinoid immunization elicited high levels of neutralizing Abs to hVEGF in mice and that purified IgGs from these immunized animals prevented xenografted human tumor growth as effectively as bevacizumab.
Results
Immune Reaction to VEGF of Mice After VEGF Kinoid Immunization. mVEGF and hVEGF kinoid heterocomplexes, obtained by treating a mixture of native KLH and mVEGF 164 or hVEGF 165, respectively, with glutaraldehyde [see supporting information (SI) Fig. 4 ], trigger in mice an Ab response to VEGF. Ab titers in BALB/c mice ranged between 1 and 2.5 ϫ 10 5 (expressed as the reciprocal of the serum dilution), peaked 7-30 days after boosting, and declined to 50% levels after 2 months (Fig. 1A) . These Abs belonged mainly to IgG1 (54%) and IgG2b (42%), whereas IgM and IgE levels were negligible. Similar results were observed in Swiss mice (data not shown). Hyperimmune sera from VEGF kinoid-immunized, but not from KLH-immunized, BALB/c mice inhibited the proliferation of human umbilical vein endothelial cells (HUVEC) in culture. Serum IC 50 ranged from 1/1,000 to 1/1,800 (Fig. 1B) . The anti-VEGF neutralizing capacity of the hyperimmune sera was further demonstrated by blockade of the binding of VEGF to its receptor-2 Flk-1, as assessed by ELISA (Fig. 1C) .
The anti-hVEGF Ab levels in sera from hVEGF kinoidimmunized BALB/c mice were as high as those elicited by murine kinoid immunization (data not shown). Hyperimmune sera from hVEGF kinoid-immunized, but not from KLHimmunized, mice inhibited the proliferation of HUVEC in culture (Fig. 1D ) and blocked the binding of hVEGF to its receptor-2 KDR (Fig. 1E) . IgG purified from hyperimmune anti-hVEGF sera specifically blocked the binding of hVEGF to its receptor-2 KDR (Fig. 1F) . mVEGF kinoid immunization did not trigger in mice any cell-mediated immune response to mVEGF, as assessed by both T cell proliferation and IFN-␥ release in splenocyte culture supernatants (SI Fig. 5 ). Although primary tumor was induced by i.v. tail injection at the perianal region in all mice, the number of kinoid-immunized animals showing macroscopically detectable lung metastases was significantly lower than for control KLH-immunized mice (3 of 12 vs. 9 of 12 animals, respectively; P ϭ 0.0143, 2 test). Furthermore, the number of histologically detectable lung metastases was significantly smaller in kinoid-immunized mice than in control animals (P Ͻ 0.05) ( Table 1) .
Tumor metastases were rather undifferentiated, with pleomorphic nuclei, a few mitoses, occasional necroses and mononuclear cell infiltrates, and rather small in diameter and most often subpleural localization, as shown in Fig. 2 . Whereas the kinoid-immunized mice had a very small tumor infiltrate associated with tumor and endothelial cell necrosis, the control mice displayed distinctly larger and well vascularized tumors. The major microscopic parameters are given in Table 1 . Notably, the degree of vascularization of the metastatic tumors was significantly reduced in kinoid-immunized mice, with a score mean of 0.1 vs. 1.1 in the control group (P Ͻ 0.001, 2 test).
Human Tumor Growth Inhibition Induced by Purified Polyclonal Abs
from Hyperimmune Sera. The antitumor effects of anti-hVEGF hyperimmune IgG were compared with those of bevacizumab in two xenografted tumor models ( Fig. 3A shows that in nude mice xenografted with 10 7 A673 cells, tumor growth was inhibited when animals were given eight biweekly i.p. injections of either hyperimmune IgG (40 mg/kg per dose) or bevacizumab (2 or 5 mg/kg per dose). Tumor growth inhibition, as measured by T/C % score (see Materials and Methods), was significant according to the National Cancer Institute standard (Ͻ42%) both in groups receiving hyperimmune IgG (T/C % ϭ 26-33% between days 36 and 54) and in a reference group treated with bevacizumab at 2 mg/kg per dose (T/C % ϭ 38% between days 36 and 54) (Table 3) . However, it must be noted that in the group of mice treated with bevacizumab at 5 mg/kg, the lower T/C % score reached at day 43 (56%) was not significant (Table 3) . Both the hyperimmune IgG and the two dose levels of bevacizumab were well tolerated, as evaluated by survival of treated animals, growth curve, behavior, and organ macroscopic examination at killing.
Growth of colorectal carcinoma HT29 cell line in NOD/SCID mice. Establishment and validation of the model. Preliminary in vitro experiments showed that HT29 cells released VEGF, although at a concentration lower than that of A673 (2.1 ng/ml vs. Ͼ10 ng/ml, respectively, for 10 7 cells per 24 h; data not shown). When 2 ϫ 10 5 cells were xenografted to NOD/SCID mice, the cells reproducibly generated tumors that were visible at day 15, whereas 10 6 xenografted cells produced tumors that grew too rapidly for study. We evaluated the effects on tumor cell growth inhibition of using either bevacizumab or paclitaxel (14) , or both. The tumor growth inhibition induced by paclitaxel (10 mg/kg) in combination with bevacizumab (5 mg/kg) appeared to be greater than that observed with either paclitaxel (P Ͻ 0.005) or bevacizumab alone (at the same dose) (P Ͻ 0.006). Furthermore, the inhibitory response elicited by the combined treatment was more homogeneous, particularly when compared with paclitaxel treatment alone (Fig. 3B Upper) . The combined treatment was validated by these initial results as a workable model for evaluation of the effects of anti-VEGF drugs.
Effect of anti-VEGF IgGs combined with paclitaxel on tumor growth. Fig. 3B Lower shows that, compared with control grafted mice, either anti-VEGF IgGs (8 mg/kg per dose) or bevacizumab (5 mg/kg) administered in combination with paclitaxel 10 mg/kg seven times over a period of 7 weeks markedly inhibited tumor growth. Significant antitumor activity was obtained both for hyperimmune IgGs-treated mice (T/C % ϭ 0-32%) and for the bevacizumab-treated group (T/C % ϭ 6-14%) ( Table 4 ). The inhibitory effects induced by bevacizumab and anti-VEGF IgGs were comparable and significant (P Ͻ 0.0001). As was found with the A673 model, the two treatments were well tolerated. Treated mice survived with normal growth, and organ macroscopic examinations were normal at killing. Of interest at the termination of the experiment, hVEGF was not detected in the sera of either hyperimmune IgG-or bevacizumab-treated mice but was present in untreated control mice because it is secreted by human tumors (SI Table 5 ). SI Table 5 also shows that host mVEGF was found in bevacizumab-treated mice at significantly higher levels than in hyperimmune mouse sera, as expected given that bevacizumab targets only one hVEGF epitope (15) and does not cross-react with mVEGF functional sites, in contrast to hyperimmune polyclonal IgGs (SI Fig. 6 ).
Discussion
VEGF is a pivotal molecule in the neoangiogenesis induced by malignant tumors, and it has recently been therapeutically targeted by passive immunization using anti-VEGF humanized mAbs (10) . Here, we show that blocking of VEGF can also be achieved safely by polyclonal Abs raised after active immunization with VEGF kinoid (SI Fig. 4) (13, 16) . As observed with other anti-self cytokine vaccinations (17) , mVEGF kinoid immunization triggered in mice a high, although transient, Ab response ( Fig. 1 A) but failed to induce a cellular response to mVEGF (SI Fig. 5 ). This result was predicted given the negative T cell clonal selection to self-antigens in the thymus and the regulatory T cells controlling self-antigens in the periphery.
The lack of autoimmune pathology due to the absence of T cell response to self-mVEGF, and the lack of adverse effects associated with circulating anti-VEGF neutralizing Abs during surgical interventions and subsequent wound-healing processes in kinoid-immunized mice (SI Fig. 7) , minimize the risk of iatrogenic complications after VEGF kinoid immunization. The absence of Ab-induced VEGF dysfunction in nontargeted healthy tissues was expected, given the high-affinity (K d ϭ 10 Ϫ11 M) binding of VEGF to its receptor, which cannot be significantly competed by the limited amount of autoantibodies of a lower avidity (K* d Ͻ 10 Ϫ9 M), as measured using Biacore AB (Paris, France) technology (data not shown).
Active kinoid immunization of mice in the autologous CT26 tumor model, and passive anti-hVEGF Ab administration in the two human A673 and HT29 tumor xenograft models in immunedeficient mice, proved to be therapeutically beneficial. Although blocking of VEGF by mAbs in combination with chemotherapy (10) is known to be effective in most cancers, here we showed that blocking mVEGF after kinoid immunization of mice reduced the growth of metastases in the lung and their vascularization but had no effect on the primary tumor cell growth, confirming that VEGF plays an essential role in the formation and growth of tumor metastases, rather than in cell proliferation of the primary engrafted tumor.
When administered to tumor-xenografted immune-deficient mice, either alone as in the A673 rhabdomyosarcoma cell model or in combination with chemotherapy (paclitaxel) as in the colorectal carcinoma cell model, anti-VEGF IgGs purified from hyperimmune sera inhibited tumor cell growth significantly and as effectively as bevacizumab. We assumed that tumor growth inhibition was mediated by antiangiogenic effects induced by either anti-hVEGF hyperimmune IgGs or bevacizumab. This assumption accounted for the selection of the A673 cell line, a high VEGF producer (18) , as a reference tumor target to evaluate the efficacy of antiangiogenic agents, including antihVEGF mAbs. Using this model, we showed that like bevacizumab, anti-hVEGF hyperimmune IgGs, as the sole treatment, were effective in inhibiting A673 tumor growth (Fig. 3A) . We further investigated the effects of anti-hVEGF Abs on HT29 human colon cells releasing VEGF, although at a much lower rate than the A673 cells. Whereas paclitaxel administered alone had, as expected, only a mild inhibitory effect on tumor growth (Fig. 3B Upper) , its association with either bevacizumab or anti-hVEGF hyperimmune IgGs reduced tumor growth dramatically (Fig. 3B Lower) . Indeed, in our study anti-hVEGF Abs did not substitute for, but rather acted as an adjunct treatment synergizing with, conventional chemotherapy, as is recommended in clinical protocols for cancer treatment (10) . The growth dependency on VEGF of tumors was further supported by the correlation between tumor growth inhibition and lack of circulating hVEGF in Ab-treated animals, whereas hVEGF was present in the sera of control xenografted mice at concentrations grossly paralleling the hVEGF secreted during tumor growth (SI Table 5 ).
Targeting of VEGF bioactivity is considered to be a powerful approach to cancer therapy, especially when combined with chemotherapy (6, 10) . Here, we demonstrate (i) that mVEGF kinoid immunization is safe, inducing polyclonal autoantibodies that neutralized mVEGF bioactivity (Fig. 1 A-C) and further inhibited the growth of experimental tumor metastases in the murine CT26 model (Fig. 2) and (ii) that polyclonal hVEGF Abs induced by hVEGF kinoid immunization (Fig. 1 D-F) inhibited the growth of human tumors releasing VEGF in murine xenograft models (Fig. 3) . Altogether, these results support the concept that hVEGF kinoid immunization represents an adjuvant therapeutic approach to conventional treatments for tumors that release VEGF either spontaneously or after radiotherapy (19, 20) or chemotherapy, as reported for carboplatin (21) . Compared with anti-VEGF mAb therapy, active immunization with the kinoid described here has the following advantages: (i) absence of anti-idiotypic Abs; (ii) a low frequency of boosters immunizations (2-3/yr), which fosters patient compliance; and (iii) low cost (22) . Furthermore, monitoring the frequency of vaccine boosters allows maintenance of effective levels of circulating VEGF Abs, which is in keeping with the logic of metronomic scheduling treatments currently in development (23) . The present study suggests the need for preclinical development of the hVEGF kinoid vaccine to further evaluate and determine its optimal use in clinical trials. Cells. HUVECs were collected as described elsewhere (24) . CT26 cells are a BALB/c (H-2d) carcinogen-induced, undifferentiated colon carcinoma (25) . Human A673 rhabdomyosarcoma and HT29 colon adenocarcinoma cell lines were obtained from the American Type Culture Collection (LGC-Promotech, Nancy, France). Immunizations. Induction of anti-m/hVEGF-specific Abs in BALB/c mice was carried out as follows. Mice were given two i.m. injections 3 weeks apart of either murine or human VEGF kinoid (30 g) emulsified at a 1:1 ratio in Complete Freund's Adjuvant (Sigma) for priming and in Incomplete Freund's Adjuvant (SEPPIC) for boosting. When indicated, IFA was used as adjuvant for both injections. Control groups were treated similarly, except that kinoid was replaced by modified KLH or NaCl.
Materials and Methods
Anti-VEGF IgGs and mAbs. IgGs were purified from hyperimmune sera by using a solid-phase protein G column. Purified hyperimmune IgGs, which inhibit the binding of VEGF to its receptor with an IC 50 of 600-900 g/ml, were administered i.p. to Swiss nude or NOD/SCID mice at doses of 0.25-1.25 mg per injection in a volume of 100-200 l, corresponding to 8-40 mg/kg body weight as assessed by ELISA. Bevacizumab was administered by i.p. injections of 100 l containing 50-250 g, corresponding to therapeutic dose of 2-10 mg/kg body weight.
In Vivo Experimental Design. Experimental lung metastasis in syngeneic CT26 colorectal-grafted BALB/c mice. CT26 tumor cell suspensions (5 ϫ 10 5 ) were injected i.v. into mVEGF kinoid-or mKLHimmunized BALB/c mice into the tail vein 10 days after the last immunization. For ethical reasons, the majority of mice were killed at 4 weeks due to the growth of large primary tumors at the perianal region; a few of the mice were killed at 6 weeks. Lungs were perfused first with saline and then with 4% formaldehyde for histology.
Human xenograft tumor models. Two different xenograft tumor models were used to evaluate the efficacy of purified hyperimmune IgGs in comparison with bevacizumab. Cancer cell lines (10 7 A673 cells or 2 ϫ 10 5 HT29 cells) were injected s.c. in animals at treatment onset.
A673 rhabdomyosarcoma tumors. Forty-four Swiss nude mice randomly allotted to four groups received repeated i.p. injections 3 days apart for 24 days, as follows: group 1 (n ϭ 12), bevacizumab at 2 mg/kg body weight; group 2 (n ϭ 12), bevacizumab at 5 mg/kg body weight; group 3 (n ϭ 8), hyperimmune IgGs at 40 mg/kg body weight; group 4 (n ϭ 12), untreated control group.
HT29 colon tumors. Thirty NOD/SCID mice were randomly divided into one control and two experimental groups of 10 mice each. Experimental groups that received once-a-week i.p. injection of paclitaxel (10 mg) were injected i.p. with 5 mg/kg bevacizumab (group 1) or with 8 mg/kg hyperimmune IgGs (group 2) twice during the first week and once in each of the following 5 weeks. The control group received the same number of i.p. injections of saline.
Monitoring of human-tumor-bearing mice. Safety and tumor growth as a biomarker for efficacy were taken as major endpoints for follow-up. As toxicity parameters, body weight, survival, clinical signs, and behavior were recorded for all mice twice a week throughout the course of the experiment, and macroscopic examination of visceral organs was performed at killing. The length and width of tumors were measured twice a week with a caliper, and the volume of the tumors was calculated using the formula: Tumor volume ϭ (width 2 ϫ length)/2. The weight of tumors at killing was in accordance with the calculated volume. Tumor growth inhibition (T/C %), defined as the ratio of the median tumor volume for the treated vs. control group was calculated as T/C % ϭ [(median tumor volume of treated group at day X)/(median tumor volume of control group at day X)] ϫ 100. The optimal value is the minimal T/C % ratio reflecting the maximal tumor growth inhibition achieved. The effective criteria for the T/C % ratio according to the National Cancer Institute standard is Ͻ42% (26) . m/hVEGF Bioassay. m/hVEGF activity was assessed by using the HUVEC proliferation assay. HUVECs (5 ϫ 10 3 ) were seeded in accordance with Soker et al. (27) . Cell proliferation was measured by [ 3 H]thymidine incorporation, as described in ref. 28 . The neutralizing titer was expressed as the reciprocal of the serum or Ig dilution that neutralizes 50% of VEGF activity, as calculated from duplicate measurements. m/hVEGF and Receptors Assays. Serum anti-m/hVEGF Ab titer was assessed by ELISA. Inhibition by serum or IgGs of the binding of VEGF to its receptor-2 was also tested by ELISA, using precoated plates with 50 ng per well of VEGF-R-2 (9).
Histology. H&E-stained paraffin sections were blindly examined by two independent observers. The number of lung metastases was counted on six consecutive lung sections, and the morphological parameters (see Table 1 ) were assessed with a semiquantitative score indicating increasing severity (0-3). The mean scores and SD are given in ref. 29 .
Statistical Analysis. All statistical analyses were performed using StatView software (Abacus Concept, Berkeley, CA). Statistical analyses of the toxicity and efficacy of treatment (body weight, tumor volume) were performed using the Bonferroni-Dunn test (ANOVA comparison).
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